Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Submitted by
admin
on September 26, 2013 - 8:19am
Source:
Yahoo/Fly on the Wall
News Tags:
Exelixis
cabozantinib
metastatic castration-resistant prostate cancer
Headline:
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Do Not Allow Advertisers to Use My Personal information
